BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zoldonrasib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zoldonrasib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06040541-2827@assetmemo.bio
DTSTAMP:20261121T005230Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zoldonrasib: Phase 1 readout est. (NCT06040541)
DESCRIPTION:Zoldonrasib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors\nEstimat
 ed primary completion: 31 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/zoldonrasib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06040541
URL:https://assetmemo.bio/drug/zoldonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06162221-2827@assetmemo.bio
DTSTAMP:20261121T005230Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Zoldonrasib: Phase 1/2 readout est. (NCT06162221)
DESCRIPTION:Zoldonrasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC\nEs
 timated primary completion: June 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/zoldonrasib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06162221
URL:https://assetmemo.bio/drug/zoldonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06922591-2827@assetmemo.bio
DTSTAMP:20261121T005230Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Zoldonrasib: Phase 1/2 readout est. (NCT06922591)
DESCRIPTION:Zoldonrasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy to Evaluate the Safety\, Tolerability & Efficacy of TNG462 in Combina
 tion in PDAC & NSCLC Patients\nEstimated primary completion: June 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/zoldonrasib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06922591
URL:https://assetmemo.bio/drug/zoldonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445062-2827@assetmemo.bio
DTSTAMP:20261121T005230Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Zoldonrasib: Phase 1/2 readout est. (NCT06445062)
DESCRIPTION:Zoldonrasib\, phase 1/2.\nStudy: Study of RAS(ON) Inhibitors in
  Patients With Gastrointestinal Solid Tumors\nEstimated primary completion
 : 30 September 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 zoldonrasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06445062
URL:https://assetmemo.bio/drug/zoldonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07621718-2827@assetmemo.bio
DTSTAMP:20261121T005230Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Zoldonrasib: Phase 3 readout est. (NCT07621718)
DESCRIPTION:Zoldonrasib\, phase 3\, Pancreatic Cancer.\nStudy: Study of Zol
 donrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigat
 or's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancre
 atic Adenocarcinoma ( RASolute 305 )\nEstimated primary completion: 30 Dec
 ember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zoldonras
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7621718
URL:https://assetmemo.bio/drug/zoldonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07805954-2827@assetmemo.bio
DTSTAMP:20261121T005230Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Zoldonrasib: Phase 3 readout est. (NCT07805954)
DESCRIPTION:Zoldonrasib\, phase 3\, Pancreatic Cancer.\nStudy: Study of Zol
 donrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Na
 b-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancr
 eatic Adenocarcinoma\nEstimated primary completion: March 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/zoldonrasib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07805954
URL:https://assetmemo.bio/drug/zoldonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07397338-2827@assetmemo.bio
DTSTAMP:20261121T005230Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Zoldonrasib: Phase 1/2 readout est. (NCT07397338)
DESCRIPTION:Zoldonrasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients Wit
 h Solid Tumors\nEstimated primary completion: May 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/zoldonrasib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07397338
URL:https://assetmemo.bio/drug/zoldonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07777822-2827@assetmemo.bio
DTSTAMP:20261121T005230Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Zoldonrasib: Phase 3 readout est. (NCT07777822)
DESCRIPTION:Zoldonrasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Z
 oldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mut
 ated NSCLC\nEstimated primary completion: October 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/zoldonrasib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07777822
URL:https://assetmemo.bio/drug/zoldonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
